Pharmacokinetics of a high dose of gentamicin administered intravenously or intramuscularly to horses

K G Magdesian, Patricia M. Hogan, Noah D. Cohen, Gordon W. Brumbaugh, William V. Bernard

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective - To evaluate pharmacokinetics of a high dose of gentamicin administered IV or IM to horses. Design - Repeated-measures study. Animals - 6 clinically normal female adult stock-type horses. Procedure - All horses were given gentamicin (6.6 mg/kg [3 mg/lb] of body weight), IV and IM, in a two-way cross-over design. Serum gentamicin concentrations were measured during a 24-hour period. Results - Plasma concentration curves were consistent with a two-compartment model. Maximum plasma gentamicin concentrations were 71.9 ± 15.7 μg/ml (0 hours after injection) and 22.0 ± 4.9 μg/ml (1.31 hours after injection) and 22.0 ± 4.9 μg/ml (1.31 hours after injection) for the IV and IM groups, respectively. Area under the curve (AUC) was 116.6 ± 14.5 and 116.3 ± 14.6 μg·h/ml for the IV and IM groups, respectively. Elimination half-life for the IV group was 3.0 ± 2.8 hours. Trough concentrations were < 2 μg/ml for > 15 and > 12 hours for the IV and IM groups, respectively. Significant changes were not detected in clinicopathologic variables before and after administration of gentamicin. Clinical Implications - Administration of a high dose of gentamicin IV or IM resulted in peak plasma concentrations, AUC, and minimum trough plasma concentrations. Results indicate once-daily administration of gentamicin might be as efficacious and safe as multiple-dose daily administration in accordance with traditional low-dose regimens, similar to those used in other species.

Original languageEnglish (US)
Pages (from-to)1007-1011
Number of pages5
JournalJournal of the American Veterinary Medical Association
Volume213
Issue number7
StatePublished - Oct 1 1998

Fingerprint

gentamicin
Gentamicins
pharmacokinetics
Horses
Pharmacokinetics
horses
dosage
Injections
Area Under Curve
injection
intravenous injection
Cross-Over Studies
half life
Half-Life
Body Weight
body weight
Serum
animals

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pharmacokinetics of a high dose of gentamicin administered intravenously or intramuscularly to horses. / Magdesian, K G; Hogan, Patricia M.; Cohen, Noah D.; Brumbaugh, Gordon W.; Bernard, William V.

In: Journal of the American Veterinary Medical Association, Vol. 213, No. 7, 01.10.1998, p. 1007-1011.

Research output: Contribution to journalArticle

Magdesian, K G ; Hogan, Patricia M. ; Cohen, Noah D. ; Brumbaugh, Gordon W. ; Bernard, William V. / Pharmacokinetics of a high dose of gentamicin administered intravenously or intramuscularly to horses. In: Journal of the American Veterinary Medical Association. 1998 ; Vol. 213, No. 7. pp. 1007-1011.
@article{ec61f231085b4cbea336e37c8af43da3,
title = "Pharmacokinetics of a high dose of gentamicin administered intravenously or intramuscularly to horses",
abstract = "Objective - To evaluate pharmacokinetics of a high dose of gentamicin administered IV or IM to horses. Design - Repeated-measures study. Animals - 6 clinically normal female adult stock-type horses. Procedure - All horses were given gentamicin (6.6 mg/kg [3 mg/lb] of body weight), IV and IM, in a two-way cross-over design. Serum gentamicin concentrations were measured during a 24-hour period. Results - Plasma concentration curves were consistent with a two-compartment model. Maximum plasma gentamicin concentrations were 71.9 ± 15.7 μg/ml (0 hours after injection) and 22.0 ± 4.9 μg/ml (1.31 hours after injection) and 22.0 ± 4.9 μg/ml (1.31 hours after injection) for the IV and IM groups, respectively. Area under the curve (AUC) was 116.6 ± 14.5 and 116.3 ± 14.6 μg·h/ml for the IV and IM groups, respectively. Elimination half-life for the IV group was 3.0 ± 2.8 hours. Trough concentrations were < 2 μg/ml for > 15 and > 12 hours for the IV and IM groups, respectively. Significant changes were not detected in clinicopathologic variables before and after administration of gentamicin. Clinical Implications - Administration of a high dose of gentamicin IV or IM resulted in peak plasma concentrations, AUC, and minimum trough plasma concentrations. Results indicate once-daily administration of gentamicin might be as efficacious and safe as multiple-dose daily administration in accordance with traditional low-dose regimens, similar to those used in other species.",
author = "Magdesian, {K G} and Hogan, {Patricia M.} and Cohen, {Noah D.} and Brumbaugh, {Gordon W.} and Bernard, {William V.}",
year = "1998",
month = "10",
day = "1",
language = "English (US)",
volume = "213",
pages = "1007--1011",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics of a high dose of gentamicin administered intravenously or intramuscularly to horses

AU - Magdesian, K G

AU - Hogan, Patricia M.

AU - Cohen, Noah D.

AU - Brumbaugh, Gordon W.

AU - Bernard, William V.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - Objective - To evaluate pharmacokinetics of a high dose of gentamicin administered IV or IM to horses. Design - Repeated-measures study. Animals - 6 clinically normal female adult stock-type horses. Procedure - All horses were given gentamicin (6.6 mg/kg [3 mg/lb] of body weight), IV and IM, in a two-way cross-over design. Serum gentamicin concentrations were measured during a 24-hour period. Results - Plasma concentration curves were consistent with a two-compartment model. Maximum plasma gentamicin concentrations were 71.9 ± 15.7 μg/ml (0 hours after injection) and 22.0 ± 4.9 μg/ml (1.31 hours after injection) and 22.0 ± 4.9 μg/ml (1.31 hours after injection) for the IV and IM groups, respectively. Area under the curve (AUC) was 116.6 ± 14.5 and 116.3 ± 14.6 μg·h/ml for the IV and IM groups, respectively. Elimination half-life for the IV group was 3.0 ± 2.8 hours. Trough concentrations were < 2 μg/ml for > 15 and > 12 hours for the IV and IM groups, respectively. Significant changes were not detected in clinicopathologic variables before and after administration of gentamicin. Clinical Implications - Administration of a high dose of gentamicin IV or IM resulted in peak plasma concentrations, AUC, and minimum trough plasma concentrations. Results indicate once-daily administration of gentamicin might be as efficacious and safe as multiple-dose daily administration in accordance with traditional low-dose regimens, similar to those used in other species.

AB - Objective - To evaluate pharmacokinetics of a high dose of gentamicin administered IV or IM to horses. Design - Repeated-measures study. Animals - 6 clinically normal female adult stock-type horses. Procedure - All horses were given gentamicin (6.6 mg/kg [3 mg/lb] of body weight), IV and IM, in a two-way cross-over design. Serum gentamicin concentrations were measured during a 24-hour period. Results - Plasma concentration curves were consistent with a two-compartment model. Maximum plasma gentamicin concentrations were 71.9 ± 15.7 μg/ml (0 hours after injection) and 22.0 ± 4.9 μg/ml (1.31 hours after injection) and 22.0 ± 4.9 μg/ml (1.31 hours after injection) for the IV and IM groups, respectively. Area under the curve (AUC) was 116.6 ± 14.5 and 116.3 ± 14.6 μg·h/ml for the IV and IM groups, respectively. Elimination half-life for the IV group was 3.0 ± 2.8 hours. Trough concentrations were < 2 μg/ml for > 15 and > 12 hours for the IV and IM groups, respectively. Significant changes were not detected in clinicopathologic variables before and after administration of gentamicin. Clinical Implications - Administration of a high dose of gentamicin IV or IM resulted in peak plasma concentrations, AUC, and minimum trough plasma concentrations. Results indicate once-daily administration of gentamicin might be as efficacious and safe as multiple-dose daily administration in accordance with traditional low-dose regimens, similar to those used in other species.

UR - http://www.scopus.com/inward/record.url?scp=0031726538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031726538&partnerID=8YFLogxK

M3 - Article

C2 - 9776999

AN - SCOPUS:0031726538

VL - 213

SP - 1007

EP - 1011

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 7

ER -